| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C7 |
| Uniprot No | P10643 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-843aa |
| 氨基酸序列 | MKVISLFILVGFIGEFQSFSSASSPVNCQWDFYAPWSECNGCTKTQTRRRSVAVYGQYGGQPCVGNAFETQSCEPTRGCPTEEGCGERFRCFSGQCISKSLVCNGDSDCDEDSADEDRCEDSERRPSCDIDKPPPNIELTGNGYNELTGQFRNRVINTKSFGGQCRKVFSGDGKDFYRLSGNVLSYTFQVKINNDFNYEFYNSTWSYVKHTSTEHTSSSRKRSFFRSSSSSSRSYTSHTNEIHKGKSYQLLVVENTVEVAQFINNNPEFLQLAEPFWKELSHLPSLYDYSAYRRLIDQYGTHYLQSGSLGGEYRVLFYVDSEKLKQNDFNSVEEKKCKSSGWHFVVKFSSHGCKELENALKAASGTQNNVLRGEPFIRGGGAGFISGLSYLELDNPAGNKRRYSAWAESVTNLPQVIKQKLTPLYELVKEVPCASVKKLYLKWALEEYLDEFDPCHCRPCQNGGLATVEGTHCLCHCKPYTFGAACEQGVLVGNQAGGVDGGWSCWSSWSPCVQGKKTRSRECNNPPPSGGGRSCVGETTESTQCEDEELEHLRLLEPHCFPLSLVPTEFCPSPPALKDGFVQDEGTMFPVGKNVVYTCNEGYSLIGNPVARCGEDLRWLVGEMHCQKIACVLPVLMDGIQSHPQKPFYTVGEKVTVSCSGGMSLEGPSAFLCGSSLKWSPEMKNARCVQKENPLTQAVPKCQRWEKLQNSRCVCKMPYECGPSLDVCAQDERSKRILPLTVCKMHVLHCQGRNYTLTGRDSCTLPASAEKACGACPLWGKCDAESSKCVCREASECEEEGFSICVEVNGKEQTMSECEAGALRCRGQSISVTSIRPCAAETQ |
| 预测分子量 | 93 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与C7重组蛋白相关的3篇参考文献示例(注：内容为模拟生成，实际文献需根据具体研究检索)：
1. **文献名称**: *Expression and functional characterization of recombinant human complement component C7*
**作者**: Smith A, et al.
**摘要**: 研究报道了通过哺乳动物细胞系统成功表达重组人C7蛋白，并验证其参与补体膜攻击复合物(MAC)形成的功能，证实其体外溶血活性与天然C7类似。
2. **文献名称**: *Structural insights into C7 in the assembly of the membrane attack complex*
**作者**: Zhang Y, et al.
**摘要**: 通过冷冻电镜解析重组C7蛋白与补体C5b-6复合物的结合结构，揭示C7在MAC组装中的构象变化及其与细胞膜相互作用的分子机制。
3. **文献名称**: *Therapeutic potential of recombinant C7 in complement-mediated diseases*
**作者**: Brown K, et al.
**摘要**: 在小鼠模型中评估重组C7蛋白对补体过度激活引起的组织损伤的修复作用，表明外源性C7可缓解因C7基因缺陷导致的病理表型。
(如需真实文献，建议通过PubMed或Google Scholar以关键词“recombinant complement C7”检索近期研究。)
C7 recombinant protein is a genetically engineered protein derived from the seventh component (C7) of the complement system, a critical part of the innate immune response. The complement system plays a central role in host defense, inflammation, and homeostasis, with C7 being essential for the formation of the membrane attack complex (MAC). MAC mediates pathogen lysis by inserting pores into target cell membranes. However, dysregulation of complement activation, including excessive C7 activity, is linked to autoimmune disorders, inflammatory diseases, and tissue damage.
Recombinant C7 is produced using heterologous expression systems, such as mammalian cell cultures (e.g., CHO cells) or bacterial systems, enabling large-scale purification for research and therapeutic applications. Its production addresses challenges in studying native C7. which is low in abundance and difficult to isolate from biological fluids.
In research, recombinant C7 is used to dissect MAC assembly mechanisms, model complement-related pathologies, and screen inhibitors for conditions like paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS). Therapeutically, C7-targeted strategies include inhibitory antibodies or peptides to block MAC overactivation. Conversely, recombinant C7 replacement therapy is explored for rare genetic deficiencies causing recurrent infections.
Recent advances in protein engineering have improved C7 stability and bioavailability, while structural studies using recombinant C7 have clarified its conformational dynamics during MAC formation. Despite progress, challenges remain in balancing therapeutic modulation of C7 to avoid compromising host defense. Ongoing studies aim to optimize delivery systems and assess long-term safety, positioning recombinant C7 as a pivotal tool in both basic immunology and precision medicine for complement-mediated diseases.
×
